5.44
-0.07(-1.27%)
Currency In USD
| Previous Close | 5.51 |
| Open | 5.4 |
| Day High | 5.56 |
| Day Low | 5.14 |
| 52-Week High | 12.61 |
| 52-Week Low | 3.72 |
| Volume | 2.3M |
| Average Volume | 1.32M |
| Market Cap | 619.38M |
| PE | -2.76 |
| EPS | -1.97 |
| Moving Average 50 Days | 5.19 |
| Moving Average 200 Days | 8.33 |
| Change | -0.07 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $122.41 as of May 31, 2025 at a share price of $5.44. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 4 years ago, it would be worth $2,428.57 as of May 31, 2025 at a share price of $5.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the
Cogent Biosciences Reports First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
GlobeNewswire Inc.
Apr 25, 2025 12:08 PM GMT
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from